Seres Therapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Seres Therapeutics, Inc. (MCRB) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.74 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-05
- Seres Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $1.74M, a 25.68% decline year-over-year.
- Seres Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $1.77M, a 37.35% decline year-over-year.
- Seres Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $2.48M, a 52.11% decline year-over-year.
- Seres Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $2.34M, a 57.72% decline year-over-year.
- Seres Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $10.84M, a 48.31% decline from fiscal 2024.
- Seres Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $20.97M, a 38.50% decline from fiscal 2023.
- Seres Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $34.10M, a 33.82% increase from fiscal 2022.
- Seres Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $25.48M, a 26.01% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.74M 10-Q · filed 2026-08-05 | $3.50M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2026-03-31 | $1.77M 10-Q · filed 2026-08-05 | |||
| 2025-12-31 | $10.84M 10-K · filed 2026-03-12 | |||
| 2025-09-30 | $2.48M 10-Q · filed 2025-11-05 | $4.82M derived: sum of 2 quarters · filed 2026-08-05 | $7.64M derived: sum of 3 quarters · filed 2026-08-05 | |
| 2025-06-30 | $2.34M 10-Q · filed 2026-08-05 | $5.16M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2025-03-31 | $2.82M 10-Q · filed 2026-08-05 | |||
| 2024-12-31 | $20.97M 10-K · filed 2026-03-12 | |||
| 2024-09-30 | $5.18M 10-Q · filed 2025-11-05 | $10.72M derived: sum of 2 quarters · filed 2025-11-05 | $17.21M derived: sum of 3 quarters · filed 2025-11-05 | |
| 2024-06-30 | $5.53M 10-Q · filed 2025-11-05 | $12.02M derived: sum of 2 quarters · filed 2025-11-05 | ||
| 2024-03-31 | $6.49M 10-Q · filed 2025-11-05 | |||
| 2023-12-31 | $34.10M 10-K · filed 2026-03-12 | |||
| 2023-09-30 | $8.67M 10-Q · filed 2024-11-13 | $22.16M derived: sum of 2 quarters · filed 2024-11-13 | $29.02M derived: sum of 3 quarters · filed 2024-11-13 | |
| 2023-06-30 | $13.49M 10-Q · filed 2024-11-13 | $20.34M derived: sum of 2 quarters · filed 2024-11-13 | ||
| 2023-03-31 | $6.85M 10-Q · filed 2024-11-13 | |||
| 2022-12-31 | $25.48M 10-K · filed 2025-03-13 | |||
| 2022-09-30 | $6.36M 10-Q · filed 2023-11-02 | $13.11M derived: sum of 2 quarters · filed 2023-11-02 | $18.19M derived: sum of 3 quarters · filed 2023-11-02 | |
| 2022-06-30 | $6.75M 10-Q · filed 2023-11-02 | $11.83M derived: sum of 2 quarters · filed 2023-11-02 | ||
| 2022-03-31 | $5.08M 10-Q · filed 2023-11-02 | |||
| 2021-12-31 | $20.22M 10-K · filed 2024-03-05 | |||
| 2021-09-30 | $5.85M 10-Q · filed 2022-11-02 | $10.92M derived: sum of 2 quarters · filed 2022-11-02 | $14.55M derived: sum of 3 quarters · filed 2022-11-02 | |
| 2021-06-30 | $5.08M 10-Q · filed 2022-11-02 | $8.70M derived: sum of 2 quarters · filed 2022-11-02 | ||
| 2021-03-31 | $3.62M 10-Q · filed 2022-11-02 | |||
| 2020-12-31 | $8.82M 10-K · filed 2023-03-07 | |||
| 2020-09-30 | $2.25M 10-Q · filed 2021-11-10 | $4.16M derived: sum of 2 quarters · filed 2021-11-10 | $6.12M derived: sum of 3 quarters · filed 2021-11-10 | |
| 2020-06-30 | $1.91M 10-Q · filed 2021-11-10 | $3.87M derived: sum of 2 quarters · filed 2021-11-10 | ||
| 2020-03-31 | $1.96M 10-Q · filed 2021-11-10 | |||
| 2019-12-31 | $8.34M 10-K · filed 2022-03-01 | |||
| 2019-09-30 | $2.04M 10-Q · filed 2020-11-09 | $4.13M derived: sum of 2 quarters · filed 2020-11-09 | $6.20M derived: sum of 3 quarters · filed 2020-11-09 | |
| 2019-06-30 | $2.10M 10-Q · filed 2020-11-09 | $4.16M derived: sum of 2 quarters · filed 2020-11-09 | ||
| 2019-03-31 | $2.06M 10-Q · filed 2020-11-09 | |||
| 2018-12-31 | $16.64M 10-K · filed 2021-03-02 | |||
| 2018-09-30 | $4.32M 10-Q · filed 2019-11-05 | $8.65M derived: sum of 2 quarters · filed 2019-11-05 | $12.89M derived: sum of 3 quarters · filed 2019-11-05 | |
| 2018-06-30 | $4.33M 10-Q · filed 2019-11-05 | $8.57M derived: sum of 2 quarters · filed 2019-11-05 | ||
| 2018-03-31 | $4.24M 10-Q · filed 2019-11-05 | |||
| 2017-12-31 | $17.36M 10-K · filed 2020-03-02 | |||
| 2016-12-31 | $16.86M 10-K · filed 2019-03-06 | |||
| 2015-12-31 | $2.79M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $5.29M derived: sum of 2 quarters · filed 2018-03-08 | $9.69M 10-K · filed 2018-03-08 | |
| 2015-09-30 | $2.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $6.91M 10-Q · filed 2015-11-12 | ||
| 2015-06-30 | $4.40M 10-Q · filed 2015-08-10 | |||
| 2014-12-31 | $2.07M 10-K · filed 2017-03-16 | |||
| 2013-12-31 | $209.00K 10-K · filed 2016-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |